Ocrevus
What Ocrevus is used for
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Ocrevus
- Active substance
- ocrelizumab
- Disease area
- Multiple Sclerosis
- Medicine group
- Immunosuppressants
- ATC code
- L04AG08
- Marketing authorisation holder
- Roche Registration GmbH
- Authorised in the EU since
- 2018
Official information
In the USA
Same active substance: Ocrevus Zunovo, Ocrevus
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ocrevus used for?
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
What is the active substance in Ocrevus?
Ocrevus contains ocrelizumab.
Who makes Ocrevus?
The EU marketing authorisation holder is Roche Registration GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU